CD36 and neoplasm: This suggests that CD36 may drive cholesterol metabolic reprogramming in DLBCL by regulating de novo cholesterol synthesis in tumor cells, altering their metabolic patterns and acting as a critical driver of cholesterol metabolism in DLBCL.